2nd Rare Disease Collaboration
Date: | 15-Jul-15 to 16-Jul-15 |
Location: | Hilton Philadelphia at Penn's Landing / Philadelphia / United States |
Category: | Healthcare & Pharmaceuticals Conferences & Trade Fairs |
With more than 6,000 rare diseases recognized by the NIH, the market for orphan and ultra-orphan indications represents a major growth area for pharma and biotech companies. But low patient numbers combined with the urgency of unmet medical needs can make standard clinical trial procedures unfeasible.
ExL Pharma’s 2nd Rare Disease Collaboration Summit gives you the tools you need to build lasting partnerships with patient advocacy groups in order to construct more flexible and patient-centric clinical trial protocols and accelerate the regulatory approval of your orphan drug.
This event hosts the formation of working group relationships that harness the collective resources of industry and patient advocates, creating a working framework for shaping legislation and convincing regulators. Build best practice outputs that outlive the meeting!
ExL Pharma’s 2nd Rare Disease Collaboration Summit gives you the tools you need to build lasting partnerships with patient advocacy groups in order to construct more flexible and patient-centric clinical trial protocols and accelerate the regulatory approval of your orphan drug.
This event hosts the formation of working group relationships that harness the collective resources of industry and patient advocates, creating a working framework for shaping legislation and convincing regulators. Build best practice outputs that outlive the meeting!
Exhibitors
Gail Adinamis, Globalcare Clinical Trials, LTD, Rino Aldrighetti, Pulmonary Hypertension Association, Ronald Bartek, Friedreich's Ataxia Research Alliance (FARA), Diane Berry, Sarepta Therapeutics, PJ Brooks, NCATS/NIH, Ted Buckley, Shire, Carrie Burke, Shire, Nina DiPrimio, Perlstein Lab, Pat Furlong, Parent Project Muscular Dystrophy (PPMD), Brett Kopelan, NORD, Catie Olson, Stanford University School of Medicine, Deborah O'Neil, NovaBiotics Ltd, Liz Ottinger, Therapeutics for Rare and Neglected Disease, Kari Rosbeck, Tuberous Sclerosis Alliance, Kyra Rosow, Pfizer, Inc., Yaffa Rubinstein, Office of Rare Diseases Research, NIH, Daniel Ward, Pfizer, Inc., Elizabeth White, Pfizer, Inc., Nora Yang, NIH Therapeutics for Rare and Neglected Diseases
EIN News
provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See:
- Autism News Today
- Brain Cancer News Today
- Breast Cancer News Today
- Breastfeeding News Today
- Conferences & Trade Shows Today
- Dental Industry Today
- Dietary Supplements News Today
- H1N1 News Today
- H7N9 Bird Flu News Today
- Health Insurance Exchanges News
- Healthcare Industry Today
- Healthcare Reform News Today
- Home Birth News Today
- Lung Cancer News Today
- MERS News Today
- Malaria News Today
- Marijuana News Today
- Mesothelioma News Today
- Pharmaceutical Industry Today
- Planned Parenthood News Today
- Prostate Cancer News Today
- SARS News Today
- Wellness News Today